Revised February 2018
Opioid-Related Overdose Deaths
In 2016, there were 94 opioid-related overdose deaths in Alaska—a rate of 12.5 deaths per 100,000 persons, compared to the national rate of 13.3 deaths per 100,000 persons. The rate has steadily increased from 8.7 deaths per 100,000 persons in 2010. This was mainly driven by an increasing number of heroin-related deaths totaling 49 in 2016.
Opioid Pain Reliever Prescriptions
In 2013, Alaska providers wrote 63.5 opioid prescriptions per 100 persons (approximately 468,000 prescriptions). In the same year, the average U.S. rate was 79.3. Since then, opioid prescriptions in the U.S. have declined, with an 11.3 percent decline in Alaska from 2013 to 2015, resulting in an estimated 57.0 opioid prescriptions per 100 persons (421,000 prescriptions) in 2015 (IMS Health, 2016).
Neonatal Abstinence Syndrome (NAS)
The incidence of NAS in Alaska has increased from 0.8 per 1,000 births in 2001 to 5.1 per 1,000 in 2012—a more than sixfold increase (epi.alaska.gov). The average across 28 states included in a 2013 analysis was 6.0 per 1,000 births (CDC, MMWR, 2014).
HIV Prevalence and HIV Diagnoses Attributed to Injection Drug Use (IDU)
- U.S. Incidence: In 2015, 9.1 percent (3,5941) of the 39,513 new diagnoses of HIV in the United States were attributed to IDU. Among new cases, 8.2 percent (2,6141) of cases among men and 13.2 percent (980) of cases among women were transmitted via IDU (CDC).
- U.S. Prevalence: In 2014, 955,081 Americans were living with a diagnosed HIV infection—a rate of 299.5 per 100,000 persons. Of these, 18.1 percent (131,0561) of males and 22.6 percent (52,013) of females were living with HIV attributed to IDU (CDC).
- State Incidence: Of the new HIV cases in 2015, 24 occurred in Alaska (a rate of 4 per 100,000 persons), with 2.9 percent1 of new cases in males and no new cases in females attributed to IDU (AIDSVu).
- State Prevalence: In 2014, an estimated 637 persons were living with a diagnosed HIV infection in Alaska—a rate of 106 per 100,000 persons. Of these, 21.2 percent1 of males and 16.1 percent of females were living with HIV attributed to IDU (AIDSVu).
Hepatitis C (HCV) Prevalence and HCV Diagnoses Attributed to Injection Drug Use
- U.S. Incidence: In 2015, there were 181,871 reported cases of chronic HCV and 33,900 estimated cases of acute HCV2 (CDC). Where data were available, 64.2 percent of acute cases reported IDU (CDC).
- U.S. Prevalence: An estimated 3.5 million Americans are living with HCV, including approximately 2.7 million living with chronic infections (CDC).
- State Incidence: In 2016, Alaska reported 1193 cases of HCV, including both chronic and acute cases, at a rate of 161 per 100,000 persons (Alaska, DHSS). In a subgroup of Alaska Natives, 54.4 percent had HCV attributed to IDU (vhpb.org).
- State Prevalence: As of 2010, an estimated 11,400 persons were living with HCV in Alaska (hepvu.org).
- Alaska Department of Health and Social Services, Alaska Opioid Policy Task Force
- Centers for Disease Control and Prevention, Opioid Overdose
- Centers for Disease Control and Prevention, Annual Surveillance Report of Drug-Related Risks and Outcomes (2017)
- Substance Abuse and Mental Health Services Administration, Behavioral Health Barometer Alaska, Volume 4 (2017)
- Includes transmission to individuals with injection drug use as a risk factor.
- 2015 estimate after adjusting for under-ascertainment and under-reporting. Data for 2015 were unavailable for Alaska, Arizona, Connecticut, the District of Columbia, Hawaii, Iowa, Mississippi, New Hampshire, Rhode Island, and Wyoming.
Emerging Trends & Alerts
Get more information on Emerging Trends and Alerts, we will update this page with the latest research findings as they develop.
Get this Publication
NIH Addresses the Opioid Crisis
New Opioid Overdose Materials for Patients
Find information about addiction and mental health services in your area. You can search by state or zip code online or call the number.